{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "20816188", "DateCompleted": {"Year": "2010", "Month": "09", "Day": "28"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "20"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1016/j.jaci.2010.06.043"], "ArticleDate": [], "Journal": {"ISSN": "1097-6825", "JournalIssue": {"Volume": "126", "Issue": "3", "PubDate": {"Year": "2010", "Month": "Sep"}}, "Title": "The Journal of allergy and clinical immunology", "ISOAbbreviation": "J Allergy Clin Immunol"}, "ArticleTitle": "Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone.", "Pagination": {"StartPage": "537", "EndPage": "44.e1", "MedlinePgn": "537-44.e1"}, "Abstract": {"AbstractText": ["Asthma is a known risk factor for acute ozone-associated respiratory disease. Ozone causes an immediate decrease in lung function and increased airway inflammation. The role of atopy and asthma in modulation of ozone-induced inflammation has not been determined.", "We sought to determine whether atopic status modulates ozone response phenotypes in human subjects.", "Fifty volunteers (25 healthy volunteers, 14 atopic nonasthmatic subjects, and 11 atopic asthmatic subjects not requiring maintenance therapy) underwent a 0.4-ppm ozone exposure protocol. Ozone response was determined based on changes in lung function and induced sputum composition, including airway inflammatory cell concentration, cell-surface markers, and cytokine and hyaluronic acid concentrations.", "All cohorts experienced similar decreases in lung function after ozone. Atopic and atopic asthmatic subjects had increased sputum neutrophil numbers and IL-8 levels after ozone exposure; values did not significantly change in healthy volunteers. After ozone exposure, atopic asthmatic subjects had significantly increased sputum IL-6 and IL-1beta levels and airway macrophage Toll-like receptor 4, Fc(epsilon)RI, and CD23 expression; values in healthy volunteers and atopic nonasthmatic subjects showed no significant change. Atopic asthmatic subjects had significantly decreased IL-10 levels at baseline compared with healthy volunteers; IL-10 levels did not significantly change in any group with ozone. All groups had similar levels of hyaluronic acid at baseline, with increased levels after ozone exposure in atopic and atopic asthmatic subjects.", "Atopic asthmatic subjects have increased airway inflammatory responses to ozone. Increased Toll-like receptor 4 expression suggests a potential pathway through which ozone generates the inflammatory response in allergic asthmatic subjects but not in atopic subjects without asthma."], "CopyrightInformation": "Published by Mosby, Inc."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Environmental Medicine Asthma and Lung Biology, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, NC 27599-7310, USA."}], "Identifier": [], "LastName": "Hernandez", "ForeName": "Michelle L", "Initials": "ML"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Lay", "ForeName": "John C", "Initials": "JC"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Harris", "ForeName": "Bradford", "Initials": "B"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Esther", "ForeName": "Charles R", "Initials": "CR", "Suffix": "Jr"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Brickey", "ForeName": "W June", "Initials": "WJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Bromberg", "ForeName": "Philip A", "Initials": "PA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Diaz-Sanchez", "ForeName": "David", "Initials": "D"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Devlin", "ForeName": "Robert B", "Initials": "RB"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Kleeberger", "ForeName": "Steven R", "Initials": "SR"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Alexis", "ForeName": "Neil E", "Initials": "NE"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Peden", "ForeName": "David B", "Initials": "DB"}], "GrantList": [{"GrantID": "UL1 RR025747-01", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "P30 ES010126-10", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "M01RR00046", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "P01 AT002620-01", "Acronym": "AT", "Agency": "NCCIH NIH HHS", "Country": "United States"}, {"GrantID": "KL2 RR025746-04", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "P01AT002620", "Acronym": "AT", "Agency": "NCCIH NIH HHS", "Country": "United States"}, {"GrantID": "KL2 RR025746", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "U19 AI077437-010003", "Acronym": "AI", "Agency": "NIAID NIH HHS", "Country": "United States"}, {"GrantID": "P30 ES010126", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "M01 RR000046", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "R01 ES012706-05", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "R01ES012706", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "P01 AT002620-05", "Acronym": "AT", "Agency": "NCCIH NIH HHS", "Country": "United States"}, {"GrantID": "U19 AI077437", "Acronym": "AI", "Agency": "NIAID NIH HHS", "Country": "United States"}, {"GrantID": "R01 ES012706", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "UL1RR025747", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "UL1 RR025747", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "M01 RR000046-48", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}, {"GrantID": "P01 AT002620", "Acronym": "AT", "Agency": "NCCIH NIH HHS", "Country": "United States"}, {"GrantID": "U19AI077437", "Acronym": "AI", "Agency": "NIAID NIH HHS", "Country": "United States"}, {"GrantID": "P30ES010126", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}, {"GrantID": "U19 AI077437-01", "Acronym": "AI", "Agency": "NIAID NIH HHS", "Country": "United States"}, {"GrantID": "KL2RR025746", "Acronym": "RR", "Agency": "NCRR NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Research Support, N.I.H., Extramural", "Research Support, U.S. Gov't, Non-P.H.S."]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Allergy Clin Immunol", "NlmUniqueID": "1275002", "ISSNLinking": "0091-6749"}, "ChemicalList": [{"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["immunology", "physiopathology"], "DescriptorName": "Asthma"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Flow Cytometry"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["complications", "physiopathology"], "DescriptorName": "Hypersensitivity, Immediate"}, {"QualifierName": ["chemically induced", "physiopathology"], "DescriptorName": "Inflammation"}, {"QualifierName": ["cytology", "immunology"], "DescriptorName": "Leukocytes, Mononuclear"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Respiratory Function Tests"}, {"QualifierName": [], "DescriptorName": "Young Adult"}], "CoiStatement": "Disclosure of potential conflict of interest: B. Harris has received research support from the National Institute of Environmental Health Sciences, the US Environmental Protection Agency, and Purdue Pharmaceuticals\u2013Quintiles. P. A. Bromberg has received research support from the US Environmental Protection Agency and the National Institutes of Health. D. B. Peden has consulted for GlaxoSmithKline and Funxional Therapeutics and has received research support from the National Institute of Environmental Health Sciences; the National Institute for Allergy and Infectious Diseases; the National Center for Complementary and Alternative Medicine; the National Heart, Lung, and Blood Institute; the US Environmental Protection Agency; the National Center for Research Resources. The rest of the authors have declared that they have no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Peden D. Air Pollution: Indoor and Outdoor. In: Adkinson NF Jr, Busse W, Bochner B, Holgate S, Simons FE, Lemanske R, editors. MIDDLETON'S ALLERGY: PRINCIPLES AND PRACTICE. 7 ed ed. Mosby: 2008. pp. 495\u2013508."}, {"Citation": "Bernstein JA, Alexis N, Barnes C, Bernstein IL, Nel A, Peden D, et al. Health effects of air pollution. J Allergy Clin Immunol. 2004;114:1116\u20131123.", "ArticleIdList": ["15536419"]}, {"Citation": "Peden DB. The epidemiology and genetics of asthma risk associated with air pollution. J Allergy Clin Immunol. 2005;115:213\u2013219. quiz 20.", "ArticleIdList": ["15696070"]}, {"Citation": "Peden DB, Boehlecke B, Horstman D, Devlin R. Prolonged acute exposure to 0.16 ppm ozone induces eosinophilic airway inflammation in asthmatic subjects with allergies. J Allergy Clin Immunol. 1997;100:802\u2013808.", "ArticleIdList": ["9438490"]}, {"Citation": "Kehrl HR, Peden DB, Ball B, Folinsbee LJ, Horstman D. Increased specific airway reactivity of persons with mild allergic asthma after 7.6 hours of exposure to 0.16 ppm ozone. J Allergy Clin Immunol. 1999;104:1198\u20131204.", "ArticleIdList": ["10589001"]}, {"Citation": "Ball BA, Folinsbee LJ, Peden DB, Kehrl HR. Allergen bronchoprovocation of patients with mild allergic asthma after ozone exposure. J Allergy Clin Immunol. 1996;98:563\u2013572.", "ArticleIdList": ["8828534"]}, {"Citation": "Jorres R, Nowak D, Magnussen H. The effect of ozone exposure on allergen responsiveness in subjects with asthma or rhinitis. Am J Respir Crit Care Med. 1996;153:56\u201364.", "ArticleIdList": ["8542163"]}, {"Citation": "Khatri SB, Holguin FC, Ryan PB, Mannino D, Erzurum SC, Teague WG. Association of ambient ozone exposure with airway inflammation and allergy in adults with asthma. J Asthma. 2009;46:777\u2013785.", "ArticleIdList": ["PMC2837943", "19863280"]}, {"Citation": "Boehlecke B, Hazucha M, Alexis NE, Jacobs R, Reist P, Bromberg PA, et al. Low-dose airborne endotoxin exposure enhances bronchial responsiveness to inhaled allergen in atopic asthmatics. J Allergy Clin Immunol. 2003;112:1241\u20131243.", "ArticleIdList": ["14657891"]}, {"Citation": "Eldridge MW, Peden DB. Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma. J Allergy Clin Immunol. 2000;105:475\u2013481.", "ArticleIdList": ["10719296"]}, {"Citation": "Schaumann F, Muller M, Braun A, Luettig B, Peden DB, Hohlfeld JM, et al. Endotoxin augments myeloid dendritic cell influx into the airways in patients with allergic asthma. Am J Respir Crit Care Med. 2008;177:1307\u20131313.", "ArticleIdList": ["PMC2427055", "18388357"]}, {"Citation": "Lay JC, Alexis NE, Kleeberger SR, Roubey RA, Harris BD, Bromberg PA, et al. Ozone enhances markers of innate immunity and antigen presentation on airway monocytes in healthy individuals. J Allergy Clin Immunol. 2007;120:719\u2013722.", "ArticleIdList": ["17586033"]}, {"Citation": "Alexis NE, Lay JC, Haczku A, Gong H, Linn W, Hazucha MJ, et al. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. Environ Health Perspect. 2008;116:799\u2013805.", "ArticleIdList": ["PMC2430237", "18560537"]}, {"Citation": "Cho HY, Kleeberger SR. Genetic mechanisms of susceptibility to oxidative lung injury in mice. Free Radic Biol Med. 2007;42:433\u2013445.", "ArticleIdList": ["17275675"]}, {"Citation": "Hollingsworth JW, 2nd, Cook DN, Brass DM, Walker JK, Morgan DL, Foster WM, et al. The role of Toll-like receptor 4 in environmental airway injury in mice. Am J Respir Crit Care Med. 2004;170:126\u2013132.", "ArticleIdList": ["15020293"]}, {"Citation": "Kleeberger SR, Reddy S, Zhang LY, Jedlicka AE. Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. Am J Respir Cell Mol Biol. 2000;22:620\u2013627.", "ArticleIdList": ["10783135"]}, {"Citation": "Becker S, Madden MC, Newman SL, Devlin RB, Koren HS. Modulation of human alveolar macrophage properties by ozone exposure in vitro. Toxicol Appl Pharmacol. 1991;110:403\u2013415.", "ArticleIdList": ["1658983"]}, {"Citation": "Janic B, Umstead TM, Phelps DS, Floros J. An in vitro cell model system for the study of the effects of ozone and other gaseous agents on phagocytic cells. J Immunol Methods. 2003;272:125\u2013134.", "ArticleIdList": ["12505718"]}, {"Citation": "Janic B, Umstead TM, Phelps DS, Floros J. Modulatory effects of ozone on THP-1 cells in response to SP-A stimulation. Am J Physiol Lung Cell Mol Physiol. 2005;288:L317\u2013L325.", "ArticleIdList": ["15466251"]}, {"Citation": "Ahmad S, Ahmad A, McConville G, Schneider BK, Allen CB, Manzer R, et al. Lung epithelial cells release ATP during ozone exposure: signaling for cell survival. Free Radic Biol Med. 2005;39:213\u2013226.", "ArticleIdList": ["15964513"]}, {"Citation": "Cho HY, Morgan DL, Bauer AK, Kleeberger SR. Signal transduction pathways of tumor necrosis factor--mediated lung injury induced by ozone in mice. Am J Respir Crit Care Med. 2007;175:829\u2013839.", "ArticleIdList": ["PMC1899292", "17255564"]}, {"Citation": "Jaspers I, Flescher E, Chen LC. Ozone-induced IL-8 expression and transcription factor binding in respiratory epithelial cells. Am J Physiol. 1997;272:L504\u2013L511.", "ArticleIdList": ["9124608"]}, {"Citation": "Bosson J, Stenfors N, Bucht A, Helleday R, Pourazar J, Holgate ST, et al. Ozone-induced bronchial epithelial cytokine expression differs between healthy and asthmatic subjects. Clin Exp Allergy. 2003;33:777\u2013782.", "ArticleIdList": ["12801312"]}, {"Citation": "Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol. 1996;97:1288\u20131296.", "ArticleIdList": ["8648025"]}, {"Citation": "Takanashi S, Hasegawa Y, Kanehira Y, Yamamoto K, Fujimoto K, Satoh K, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J. 1999;14:309\u2013314.", "ArticleIdList": ["10515406"]}, {"Citation": "Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11:1173\u20131179.", "ArticleIdList": ["16244651"]}, {"Citation": "Taylor KR, Yamasaki K, Radek KA, Di Nardo A, Goodarzi H, Golenbock D, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem. 2007;282:18265\u201318275.", "ArticleIdList": ["17400552"]}, {"Citation": "Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195:99\u2013111.", "ArticleIdList": ["PMC2196009", "11781369"]}, {"Citation": "Garantziotis S, Li Z, Potts EN, Kimata K, Zhuo L, Morgan DL, et al. Hyaluronan mediates ozone-induced airway hyperresponsiveness in mice. J Biol Chem. 2009;284:11309\u201311317.", "ArticleIdList": ["PMC2670136", "19164299"]}, {"Citation": "Garantziotis S, Li Z, Potts EN, Lindsey JY, Stober VP, Polosukhin VV, et al. TLR4 is Necessary for Hyaluronan-mediated Airway Hyperresponsiveness After Ozone Inhalation. Am J Respir Crit Care Med. 2009", "ArticleIdList": ["PMC2868499", "20007931"]}, {"Citation": "Alexis NE, Zhou H, Lay JC, Harris B, Hernandez ML, Lu TS, et al. The glutathione-S-transferase Mu 1 null genotype modulates ozone-induced airway inflammation in human subjects. J Allergy Clin Immunol. 2009;124:1222\u20131228. e5.", "ArticleIdList": ["PMC3038610", "19796798"]}, {"Citation": "Knudson RJ, Burrows B, Lebowitz MD. The maximal expiratory flow-volume curve: its use in the detection of ventilatory abnormalities in a population study. Am Rev Respir Dis. 1976;114:871\u2013879.", "ArticleIdList": ["791036"]}, {"Citation": "Alexis NE, Eldridge MW, Peden DB. Effect of inhaled endotoxin on airway and circulating inflammatory cell phagocytosis and CD11b expression in atopic asthmatic subjects. J Allergy Clin Immunol. 2003;112:353\u2013361.", "ArticleIdList": ["12897742"]}, {"Citation": "Alexis NE, Lay JC, Zeman K, Bennett WE, Peden DB, Soukup JM, et al. Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers. J Allergy Clin Immunol. 2006;117:1396\u20131403.", "ArticleIdList": ["16751003"]}, {"Citation": "Lay JC, Alexis NE, Zeman KL, Peden DB, Bennett WD. In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers. Thorax. 2009;64:313\u2013320.", "ArticleIdList": ["PMC4450817", "19052052"]}, {"Citation": "Vagaggini B, Taccola M, Cianchetti S, Carnevali S, Bartoli ML, Bacci E, et al. Ozone exposure increases eosinophilic airway response induced by previous allergen challenge. Am J Respir Crit Care Med. 2002;166:1073\u20131077.", "ArticleIdList": ["12379550"]}, {"Citation": "Vagaggini B, Carnevali S, Macchioni P, Taccola M, Fornai E, Bacci E, et al. Airway inflammatory response to ozone in subjects with different asthma severity. Eur Respir J. 1999;13:274\u2013280.", "ArticleIdList": ["10065667"]}, {"Citation": "Alexis N, Urch B, Tarlo S, Corey P, Pengelly D, O'Byrne P, et al. Cyclooxygenase metabolites play a different role in ozone-induced pulmonary function decline in asthmatics compared to normals. Inhal Toxicol. 2000;12:1205\u20131224.", "ArticleIdList": ["11114789"]}, {"Citation": "Passannante AN, Hazucha MJ, Bromberg PA, Seal E, Folinsbee L, Koch G. Nociceptive mechanisms modulate ozone-induced human lung function decrements. J Appl Physiol. 1998;85:1863\u20131870.", "ArticleIdList": ["9804592"]}, {"Citation": "Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature. 1999;402:B24\u2013B30.", "ArticleIdList": ["10586892"]}, {"Citation": "Braunstahl GJ, Fokkens WJ, Overbeek SE, KleinJan A, Hoogsteden HC, Prins JB. Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin Exp Allergy. 2003;33:579\u2013587.", "ArticleIdList": ["12752585"]}, {"Citation": "Brown JL, Behndig AF, Sekerel BE, Pourazar J, Blomberg A, Kelly FJ, et al. Lower airways inflammation in allergic rhinitics: a comparison with asthmatics and normal controls. Clin Exp Allergy. 2007;37:688\u2013695.", "ArticleIdList": ["17456216"]}, {"Citation": "Hollingsworth JW, Maruoka S, Li Z, Potts EN, Brass DM, Garantziotis S, et al. Ambient ozone primes pulmonary innate immunity in mice. J Immunol. 2007;179:4367\u20134375.", "ArticleIdList": ["17878331"]}, {"Citation": "Ke B, Shen XD, Tsuchihashi S, Gao F, Araujo JA, Busuttil RW, et al. Viral interleukin-10 gene transfer prevents liver ischemia-reperfusion injury: Toll-like receptor-4 and heme oxygenase-1 signaling in innate and adaptive immunity. Hum Gene Ther. 2007;18:355\u2013366.", "ArticleIdList": ["17439357"]}, {"Citation": "Abdollahi-Roodsaz S, Joosten LA, Koenders MI, van den Brand BT, van de Loo FA, van den Berg WB. Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation. Am J Pathol. 2009;175:2004\u20132013.", "ArticleIdList": ["PMC2774064", "19834062"]}, {"Citation": "Park JW, Taube C, Swasey C, Kodama T, Joetham A, Balhorn A, et al. Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone. Am J Respir Cell Mol Biol. 2004;30:830\u2013836.", "ArticleIdList": ["14754758"]}, {"Citation": "Konno S, Gonokami Y, Kurokawa M, Kawazu K, Asano K, Okamoto K, et al. Cytokine concentrations in sputum of asthmatic patients. Int Arch Allergy Immunol. 1996;109:73\u201378.", "ArticleIdList": ["8527954"]}, {"Citation": "Pujol JL, Cosso B, Daures JP, Clot J, Michel FB, Godard P. Interleukin-1 release by alveolar macrophages in asthmatic patients and healthy subjects. Int Arch Allergy Appl Immunol. 1990;91:207\u2013210.", "ArticleIdList": ["2341202"]}, {"Citation": "Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992;89:958\u2013967.", "ArticleIdList": ["1374772"]}, {"Citation": "Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125:1028\u20131036. e13.", "ArticleIdList": ["PMC2878277", "20398920"]}, {"Citation": "Bihl F, Salez L, Beaubier M, Torres D, Lariviere L, Laroche L, et al. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol. 2003;170:6141\u20136150.", "ArticleIdList": ["12794144"]}, {"Citation": "Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, Bertin J, et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem. 2009;284:12762\u201312771.", "ArticleIdList": ["PMC2676006", "19258328"]}, {"Citation": "Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815\u20133822.", "ArticleIdList": ["1940369"]}, {"Citation": "Backus GSBAK, Cho H-Y, Peden DB, Kleeberger SR. Protective Role of IL-10 in Ozone-Induced Inflammation. International Conference of the American Thoracic Society; Proceedings of the American Thoracic Society; San Diego, CA. 2006. p. A38."}, {"Citation": "Mattes J, Collison A, Plank M, Phipps S, Foster PS. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci U S A. 2009;106:18704\u201318709.", "ArticleIdList": ["PMC2773983", "19843690"]}]}], "History": [{"Year": "2010", "Month": "1", "Day": "8"}, {"Year": "2010", "Month": "6", "Day": "4"}, {"Year": "2010", "Month": "6", "Day": "16"}, {"Year": "2010", "Month": "9", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "9", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "9", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2011", "Month": "9", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["20816188", "NIHMS230490", "PMC2949284", "10.1016/j.jaci.2010.06.043", "S0091-6749(10)01050-X"]}}], "PubmedBookArticle": []}